Author(s):
Adsul Samruddhi Subhash, Adsul Samruddhi Subhash, Wable Madhuri Sanjay
Email(s):
samuadsul03@gmail.com
DOI:
10.52711/2349-2988.2025.00038 
Address:
Adsul Samruddhi Subhash, Adsul Samruddhi Subhash, Wable Madhuri Sanjay
Swastyadarpan Pratishthan’s, Shantiniketan College of Pharmacy, A/P Dhotre (B.K.), Tal. Parner, Ahmednagar.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2025
ABSTRACT:
Ovarian cancer is the fifth most common cause of death for women overall and the leading cause of death for women diagnosed with gynecological cancers. The majority of cases are diagnosed at an advanced stage, which results in poor outcomes for this disease. The key early detection strategies include transvaginal ultrasound, a laboratory marker such as the cancer antigen-125 assay, and a detailed gynecological evaluation; however, anti-angio genic bevacizumab and Poly (ADP-ribose) polymerase (PARP) inhibitors have gained traction in the management of this gynecological malignancy in the last ten years. After the initial treatment, a high rate of recurrence has been noted. The majority of these relapsed cases are known to have a higher rate of treatment failures and are less treatable. Therefore, there is an urgent need for innovative treatment methods based on a deeper understanding of the molecular characteristics of this malignancy as well as efficient preventive and detection strategies. In addition to reviewing the epidemiology and risk factors of ovarian cancer, this article discusses some recent ongoing studies and emphasizes the evaluation and multidisciplinary approach in the care of this condition.
We use here pomegranate
Cite this article:
Adsul Samruddhi Subhash, Adsul Samruddhi Subhash, Wable Madhuri Sanjay. Pomegranate: The Savier of Ovarian Cancer. Research Journal of Science and Technology. 2025; 17(4):272-8. doi: 10.52711/2349-2988.2025.00038
Cite(Electronic):
Adsul Samruddhi Subhash, Adsul Samruddhi Subhash, Wable Madhuri Sanjay. Pomegranate: The Savier of Ovarian Cancer. Research Journal of Science and Technology. 2025; 17(4):272-8. doi: 10.52711/2349-2988.2025.00038 Available on: https://rjstonline.com/AbstractView.aspx?PID=2025-17-4-3
REFERENCES:
1. Hong MK, Ding DC. Early diagnosis of ovarian cancer: A comprehensive review of the advances, challenges, and future directions. Diagnostics. 2025 Feb 7; 15(4):406.
2. Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR. Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review. Cancers. 2022 Jun 11; 14(12):2885
3. Sahu SA, Shrivastava D. A comprehensive review of screening methods for ovarian masses: Towards earlier detection. Cureus. 2023 Nov 8; 15(11).
4. Krankenberg DJ, Muallem MZ, Pietzner K, Chekerov R, Armbrust R, Beteta C, Schöning W, Lee M, Klews J, Sehouli J. Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction. Archives of Gynecology and Obstetrics. 2024 Jun; 309(6):2821-8.
5. Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nature Reviews Clinical Oncology. 2024 May; 21(5):389-400.
6. Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. InSeminars in cancer biology 2022 Nov 1 (Vol. 86, pp. 207-223). Academic Press.
7. De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, Chiarucci F, Rosini F, Ravegnini G, Pession A, Turchetti D. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors. Diagnostics. 2021 Apr 14; 11(4):697.
8. Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno III DE, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MC. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers. 2022 Apr 29; 14(9):2230.
9. Ali AT, Al-Ani O, Al-Ani F. Epidemiology and risk factors for ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2023 Jun 14; 22(2):93-104.
10. Vaiphei SD. Understanding End-of-Life Care: Psychological Approaches to Cancer Care. Taylor and Francis; 2025 Mar 26.
11. La Marca A, Diamanti M. Factors affecting age at menopause and their relationship with ovarian reserve: A comprehensive review. The European Journal of Contraception and Reproductive Health Care. 2024 Sep 2; 29(5):245-55.
12. Bertozzi S, Londero AP, Diaz Nanez JA, Di Vora R, Baita B, La Verghetta L, Prada S, Seriau L, Mariuzzi L, Cedolini C. Breast cancer care for the aging population: a focus on age-related disparities in breast cancer treatment. BMC cancer. 2025 Mar 17; 25(1):492.
13. Mantovani G, Coada CA, Di Costanzo S, Mezzapesa F, Genovesi L, Bogani G, Raspagliesi F, Morganti AG, De Iaco P, Perrone AM. Primary or Interval Debulking Surgery for Advanced Endometrial Cancer with Carcinosis: A Systematic Review and Individual Patient Data Meta-Analysis of Survival Outcomes. Cancers. 2025 Mar 19; 17(6):1026.
14. Wang ZB, Liao DH, Lei G, Liu ZQ, Wu N, Wang J. Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II. Frontiers in Pharmacology. 2025 Feb 10; 16:1552652
15. Tsolakidis D, Kyziridis D, Panoskaltsis T, Kalakonas A, Theodoulidis V, Chatzistamatiou K, Zouzoulas D, Tentes AA. Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review. Cancers. 2025 Mar 6; 17(5):904.
16. Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nature Reviews Clinical Oncology. 2024 May; 21(5):389-400.
17. Fu Z, Taylor S, Modugno F. Lifetime ovulations and epithelial ovarian cancer risk and survival: a systematic review and meta-analysis. Gynecologic oncology. 2022 Jun 1; 165(3):650-63.
18. Didziokaite G, Biliute G, Gudaite J, Kvedariene V. Oxidative stress as a potential underlying cause of minimal and mild endometriosis-related infertility. International Journal of Molecular Sciences. 2023 Feb 14; 24(4):3809.
19. Barili V, Ambrosini E, Bortesi B, Minari R, De Sensi E, Cannizzaro IR, Taiani A, Michiara M, Sikokis A, Boggiani D, Tommasi C. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition Testing. Genes. 2024 Feb 8; 15(2):219.
20. Palleschi M. Exploring the role of rare germline variants in non-coding regions of cancer predisposition genes in triple-negative breast cancer patients.
21. Otsuka I. Mechanisms of high-grade serous carcinogenesis in the fallopian tube and ovary: current hypotheses, etiologic factors, and molecular alterations. International journal of molecular sciences. 2021 Jan; 22(9):4409.
22. Li Y, Song W, Gao P, Guan X, Wang B, Zhang L, Yao Y, Guo Y, Wang Y, Jiang S, Sun S. Global, regional, and National burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021. BMC cancer. 2025 Feb 24; 25(1):330.
23. Rees A, Villamor E, Evans D, Gooz M, Fallon C, Mina-Abouda M, Disharoon A, Eblen ST, Delaney JR. Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer. Genes. 2025 Jan 1; 16(1):42.
24. Shen Y, Cheng J, Ding Q, Tao Z. Molecular characteristics of early-and late-onset ovarian cancer: insights from multidimensional evidence. Journal of Ovarian Research. 2025 Apr 23; 18(1):83.
25. Wei YF, Ning L, Xu YL, Ma J, Li DR, Feng ZF, Liu FH, Li YZ, Xu HL, Li P, Yu YP. Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017. EClinicalMedicine. 2025 Jan 1; 79.
26. Mongiovi JM, Townsend MK, Vitonis AF, Harris HR, Doherty JA, Babic A, Hecht JL, Soong TR, Titus L, Conejo-Garcia JR, Fridley BL. Associations between parity, history of breastfeeding, and T cell profile of ovarian tumors. Cancer Epidemiology, Biomarkers and Prevention. 2025 Feb 6.
27. Zhang J, Wang M, Wu Y. Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma. Current Oncology. 2025 Apr 30; 32(5):263.
28. Haddadi R. Managing the Unseen: A Qualitative Study on Polycystic Ovary Syndrome-Related Pain and Symptom Management (Master's thesis, University of Twente).
29. Yan M, Yuan Z. Chloroplast Genome of Pomegranate. InThe Pomegranate Genome 2025 Feb 28 (pp. 70-75). CRC Press.
30. Huang Z, Foo SC, Choo WS. A review on the extraction of polyphenols from pomegranate peel for punicalagin purification: techniques, applications, and future prospects. Sustainable Food Technology. 2025.
31. Martínez-Méndez DD, Sánchez-Mundo MD, Ortiz-León LA, Álvarez-Salas LM, Rosales-García VH, Rodríguez-Campos J, Jaramillo-Flores ME. Ballota hirsuta Benth Arrests the Cell Cycle, Induces Apoptosis and Inhibits the Invasion of MCF-7 and MDA-MB-231 Cell Lines in 2D and 3D Models. International Journal of Molecular Sciences. 2025 Jun 13; 26(12):5672.
32. Al Hoque A, Begum S, Dutta D. Occurrence, Chemical Nature, and Medicinal Benefits of Flavonoids-Rutin, Kaempferol, Quercetin, Anthocyanidins, Catechins, and Flavones. InDietary Supplements and Nutraceuticals 2025 Apr 28 (pp. 1-24). Singapore: Springer Nature Singapore
33. Rauf A, Ajaj R, Akram Z, Hafeez N, Rebezov M, Shariati MA, Aljohani AS, Imran M, Tanveer F, Hemeg HA, Mubarak MS. Ferulic acid as a promising candidate for developing selective and effective anti-cancer therapies. Discover Oncology. 2025 Jul 1; 16:1214.
34. Manmuan S, Sirirak T, Tubtimsri S, Petchsomrit A, Chuenbarn T. Phytochemical analysis, antioxidant activity, and cytotoxic effects of Caulerpa lentillifera extracts inducing cell apoptosis and sub-G/G0-G1 cell cycle arrest in KON oral cancer cells. BMC Complementary Medicine and Therapies. 2025 Mar 11; 25(1):101.
35. Namwan N, Senawong G, Phaosiri C, Kumboonma P, Somsakeesit LO, Samankul A, Leerat C, Senawong T. Synergistic Anti-Cancer Activities of Curcumin Derivative CU17 Combined with Gemcitabine Against A549 Non-Small-Cell Lung Cancer Cells. Pharmaceutics. 2025 Jan 24; 17(2):158.
36. Ashaolu TJ, Lydia DE, Rehman A, Karim A, Jafari SM. Extraction and stabilization of pomegranate seed oil: a functional oil for the food industry. Journal of Food Measurement and Characterization. 2025 Jan; 19(1):167-84.
37. D'costa M, Bothe A, Das S, Kumar SU, Gnanasambandan R, Doss CG. CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells. Advances in Protein Chemistry and Structural Biology. 2023 Jan 1; 135:125-77.
38. Palani B, Vajjiravelu R, Shanmugam R, Jayakodi S. Bioactive Compounds for Inhibiting Mutated Gene (BRCA1 and BRCA2) Signaling Pathway in Ovarian Cancer Treatment. Biomedical Materials and Devices. 2025 Apr 24:1-20.
39. Nunes AR, Alves G, Falcão A, Lopes JA, Silva LR. Phenolic Acids from Fruit By-Products as Therapeutic Agents for Metabolic Syndrome: A Review. International Journal of Molecular Sciences. 2025 Apr 18; 26(8):3834.
40. Mustafa YF. Role of fruit-derived antioxidants in fighting cancer: a narrative review. Indian Journal of Clinical Biochemistry. 2025 Feb 18:1-8.
41. Nguyen TL, Ora A, Häkkinen ST, Ritala A, Räisänen R, Kallioinen-Mänttäri M, Melin K. Innovative extraction technologies of bioactive compounds from plant by-products for textile colorants and antimicrobial agents. Biomass conversion and biorefinery. 2024 Oct; 14(20):24973-5002.
42. Xu C, Chen J, Tan M, Tan Q. The role of macrophage polarization in ovarian cancer: From molecular mechanism to therapeutic potentials. Frontiers in Immunology. 2025 Apr 22; 16:1543096.
43. Bayramoğlu Ee, Çivi S. Review of tannins currently used in the leather industry. Part 1: Hydrolysable Tannins. ICAMS 2024. 2024 Oct 30:30.
44. Molnar M, Jakovljević Kovač M, Pavić V. A comprehensive analysis of diversity, structure, biosynthesis and extraction of biologically active tannins from various plant-based materials using deep eutectic solvents. Molecules. 2024 Jun 2; 29(11):2615.
45. Islam MR, Rahman MM, Dhar PS, Nowrin FT, Sultana N, Akter M, Rauf A, Khalil AA, Gianoncelli A, Ribaudo G. The role of natural and semi-synthetic compounds in ovarian cancer: Updates on mechanisms of action, current trends and perspectives. Molecules. 2023 Feb 22; 28(5):2070.
46. Semeradtova A, Liegertova M, Herma R, Capkova M, Brignole C, Del Zotto G. Extracellular vesicles in cancer´ s communication: messages we can read and how to answer. Molecular Cancer. 2025 Mar 19; 24(1):86.
47. Amer A, Shahin A. In Vitro Production of Flavonoids. Plant Specialized Metabolites: Phytochemistry, Ecology and Biotechnology. 2025 Mar 19:1-49.
48. Masyita A, Hardinasinta G, Astuti AD, Firdayani F, Mayasari D, Hori A, Nisha IN, Nainu F, Kuraishi T. Natural pigments: innovative extraction technologies and their potential application in health and food industries. Frontiers in Pharmacology. 2025 Jan 8; 15:1507108.
49. Lazić AM, Matović LR, Trišović NP, Valentić NV. Harnessing the potential of selected plant pigments in dye-sensitized solar cells: the current status. Hemijska industrija. 2025; 79(1):47-65.
50. An J, Zhang Z, Jin A, Tan M, Jiang S, Li Y. Organic Functional Groups and Their Substitution Sites in Natural Flavonoids: A Review on Their Contributions to Antioxidant, Anti‐Inflammatory, and Analgesic Capabilities. Food Science and Nutrition. 2025 May; 13(5):e70191.
51. Schwarzlmueller P, Triebig A, Assié G, Jouinot A, Theurich S, Maier T, Beuschlein F, Kobold S, Kroiss M. Steroid hormones as modulators of anti-tumoural immunity. Nature Reviews Endocrinology. 2025 Mar 24:1-3.